This Will be the Title of Your Paper

Running (Short) Title: (more than 50 characters)

**First Author’s Full Name1, Second Author’s Full Name2, Third Author’s Full Name3**

1 Name of Institution, Department Name, City, Country (first author’s affiliation), ORCID ID

2 Name of Institution, Department Name, City, Country (second author’s affiliation), ORCID ID

3 Name of Institution, Department Name, City, Country (third author’s affiliation), ORCID ID

**Corresponding Author’s information:**

Full name, address, e-mail address, telephone and/or fax number of the author responsible for manuscript preparation. Author details must not show any professional title (e.g. Managing Director), any academic title (e.g. Dr.) or any membership of any professional organization (e.g. Senior Member IEEE). To avoid confusion, the family name must be written as the last part of each author name (e.g. John A.K. Smith). The 16-digit ORCID of the author(s) should be provided (<https://orcid.org/>).

Name of Department and Institution where work was done.

**Acknowledgments:** Source(s) of financial support in the form of grants (quote the number of the grant) equipment, drugs etc. Statements and declarations regarding conflicts of interest should appear here. **For example; “The authors deny any conflict of interest.”**

Abstract

**Aim:** This template will provide you with a guide for formatting your manuscript, as per the instructions of International Dental Research. Manuscripts must be submitted in this format to be considered for publication. The general guidelines for submission to International Dental Research are in accordance with: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (N Eng J Med, 1997; 336: 309-15). Text should be one and half spaced with 12-point typeface. Margins: 2.5 cm (1 inch) at top, bottom, right, and left.

**Methodology:** Abstract should be in structured form, not exceeding 300 words, and should consist of four paragraphs labelled: Aim, Methodology, Results, and Conclusion.

**Results:** There should be no citations within the Abstract section of the manuscript.

**Conclusion:** Each summary section should begin in a new line and briefly describe, respectively, the purpose of publishing the case and the principal conclusion that authors draw from the case report.

**Keywords:** 3 to 6 keywords or short phrases, separated by commas. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (<https://www.nlm.nih.gov/mesh/MBrowser.html>).

**Introduction:**

This section should contain the scientific rationale and the aim of the study or (in case of a review) purpose of the article. Citations may begin in this section of the manuscript. Citations should be in parenthesis (1), at full size, and should be numbered in the order in which they are cited, and listed in numerical order in the bibliography section. References must be up-to-date. References selected for publication should be chosen for their importance, accessibility, and for the further reading opportunities they provide. The style of references is that of Index Medicus, examples can be found in this template’s Reference section. List all authors when there are six or fewer; when there are seven or more, list the first three, then “et al”. Avoid using abstracts or review papers as references. Unpublished observations and personal communications can not be used as references. If essential, such material may be incorporated in the appropriate place in the text.

**Material and Methods:**

This section should describe clearly the selection of observational or experimental subjects including controls, such as age, gender, inclusion and exclusion criteria, (the circumstances for rejection from the study should be clearly defined), randomization and masking (blinding) method. The protocol of data acquisition, procedures, investigated parameters, methods of measurements and apparatus should be described in sufficient detail to allow other scientists to reproduce the results. Name and references to the established methods should be given. References and brief description should be provided for methods that have been published but are not well known, whereas new or substantially modified methods should be described in detail. The reasons for using them should be provided along with the evaluation of their limitations. The drugs and other chemicals should be precisely identified including generic name, dose and route of administration. The statistical methods should be described in detail to enable verification of the reported results. Provide information on patients informed consent. Studies on patients and volunteers require informed consent documented in the text of the manuscript. Where there is any unavoidable risk of breach of privacy - e.g. in a clinical photograph or in case details - the patient's written consent to publication must be obtained and copied to the journal. If necessary, Information on approval of a Local Ethical Committee should also be provided.

**Results:**

This section should concisely and reasonably summarize the findings. Restrict tables and figures to the number needed to explain the argument of the paper and assess its support. Do not duplicate data in graphs and tables. Give numbers of observation and report exclusions or losses to observation such as dropouts from a clinical trial. Report treatment complications. The results should be presented in a logical sequence in the text, tables and illustrations. Do not repeat in the text all the data from the tables or graphs. Emphasize only important observations.

**Discussion:**

This section should deal only with new and/or important aspects of the study. Do not repeat in detail data or other material from the Background or the Results section. Include in the Discussion the implications of the findings and their limitations, including implications for future research. The discussion should confront the results of other investigations especially those quoted in the text.

In preparing your manuscript, all figures, graphics, images or photos should be saved in separate files and uploaded under the appropriate headings (ex. Figure 1, Figure 2, Graphic 1, etc.). Be sure to reference each of your figures and tables in your text. Tables should be given in the text with Table legends. We will try to place them as close to the reference as possible. Figures should be at a preferred resolution of 300 dpi, in the following formats: .jpg, .png, .tiff, .eps, .psd, .pdf. Letters, numbers, and symbols should be clear and even throughout and of sufficient size that when reduced for publication each item will still be legible. All identifiable names must be redacted from any laboratory or radiological films. If a figure has been published, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. Permission is required irrespective of authorship or publisher, except for documents in the public domain. The Titles and legends for your figures should appear at the end of the manuscript, after the references. References first cited in tables or figure legends must be numbered so that they will be in sequence with references cited in the text.

**Conclusion:**

Your conclusions should be linked with the goals of the study. State new hypotheses when warranted. Include recommendations when appropriate. Unqualified statements and conclusions not completely supported by the obtained data should be avoided.

**Acknowledgements:**

List all contributors who do not meet the criteria for authorship, such as technical assistants, writing assistants or head of department who provided only general support. Financial and other material support should be disclosed and acknowledged.

**References:**

1. **Standard journal article:** Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg MM. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med 1979;301:1382-5.
2. **Article with published erratum**: Koffler D, Reidenberg MM. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide [published erratum appears in N Engl J Med 1979;302:322-5]. N Engl J Med 1979;301: 1382-5.
3. **Article in electronic form**: Drayer DE, Koffler D. Factors in the emergence of infectious diseases. Emerg Infect Dis [serial online] 1995 Jan-Mar [cited 1996 Jun 5];1(1):[24 screens]. Available from: URL:http://www.cdc.gov/ncidod/EID/eid.htm
4. **Article, no author given:** Cancer in South Africa [editorial]. S Afr Med J 1994;84:15.
5. **Book, personal author(s)**: Ringsven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996.
6. **Book, editor(s) as author:** Norman IJ, Redfern SJ, editors. Mental health care for elderly people. New York: Churchill Livingstone; 1996.
7. **Book, Organization as author and publisher:** Institute of Medicine (US). Looking at the future of the Medicaid program. Washington: The Institute; 1992.
8. **Chapter in a book:**Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed.  New York: Raven Press; 1995. p. 465-78.
9. **Conference proceedings:** Kimura J, Shibasaki H, editors. Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier; 1996.
10. **Conference paper:**Bengtsson S, Solheim BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors. MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; 1992 Sep 6-10; Geneva, Switzerland.

**Figure Legends**

**Figure 1.** Here you would describe each figure and its significance.